Marketresearchnews

Thursday, 15 October 2020

Organ transplantation Market 2020 Share, Trend, Segmentation And Forecast To 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Organ transplantation Market over the forecast period.

Organ transplantation is the removal of organ or tissue from one individual and its placement in another. Organ transplantation can also be performed within the same individual, as tissues can be moved to a different location within the same body. Organ transplantation has become a major tool for the healthcare sector in recent decades, with organ transplantation providing a solution to many notable and concerning health issues such as nephritis and terminal heart conditions. Organ transplantation is a triumph of modern medicine and must be celebrated as one of the most ingenious solutions ever developed in the healthcare sector.

Also Read : https://www.medgadget.com/2019/12/organ-transplantation-market-size-worlds-top-10-industry-share-analysis-growing-at-9-8-cagr-during-forecast-2019-to-2023.html

The Global Organ Transplantation Market, as per the study conducted by Market Research Future (MRFR), is expected to attain a compound annual growth rate of 9.8% during the forecast period of 2018 to 2023. An increasing number of organ transplantation surgeries undertaken globally is one of the major drivers of the organ transplantation market. Increasing prevalence of chronic diseases, advancements in technology, changing lifestyle of individuals, and the rising aging population are some of the other key factors influencing the growth of the global market.

However, at the same time, it is worth noting that the high treatment cost and increasing incidences of organ failure can severely hamper the projected growth of the market.

Organ Transplantation Market Leaders

TransMedic, Inc. (US),
Transonic (US),
Novartis International AG (Switzerland),
OrganOX Limited (UK),
F. Hoffmann-La Roche Ltd. (Switzerland),
Terumo Medical Corporation (US),
Preservation Solutions, Inc. (US),
Transplant Biomedical (UK),
Accord Healthcare GmbH (Spain),
Astellas Pharma, Inc (Japan),
Pfizer, Inc. (US),
Veloxis Pharmaceuticals A/S (Denmark),
Bio Med Pvt. Ltd. (US),
GlaxoSmithKline Plc. (UK),
Sanofi (France)

Organ Transplantation Market Growth and Share Analysis by Regions

The regional segmentation of the organ transplantation market covers the following regions: Europe, Americas, Asia Pacific, and the Middle East and Africa.

America holds the largest share of the market in the global standings of organ transplantation. This is due to the increasing prevalence of chronic diseases. Other key factors influencing the growth of the market in this region are the rising aging population, an increase in the number of organ transplantation cases, and striking developments in technology.

Europe stands second in the global organ transplantation market due to various essential factors or drivers. The regional market is driven by the developed infrastructure, encouragement for the emergence of new organizations, and increasing expenditures on healthcare.

Asia Pacific is expected to grow at a notable pace in the near future and cement its position as one of the key regions in the global organ transplantation market. Factors such as fast-paced development in the healthcare industry, presence of a huge patient population pool, and the availability of skilled professionals are the major growth drivers of the market. However, in the Middle East and Africa region, the poor economical condition coupled with the limited growth of the healthcare sector is expected to be responsible for the meagre growth of the region.

Market Segmentation

The global organ transplantation market segmentation is done as per the following dynamics: type. End-users, products, and treatment.

By type, the market comprises of lungs, heart, liver, kidney, and others.

By products, the market segments into tissue products, organ preservation solutions, transplant diagnostics, and others.

By type of treatment, the market includes immunosuppressant, analgesic, and other. Immunosuppressant is narrowed down into mTOR inhibitor, calcineurin inhibitors, steroids, antiproliferative agents, and other. Whereas calcineurin inhibitors are divided into tacrolimus and cyclosporine. And, mTOR inhibitor is broken down into sirolimus and everolimus.

By type of transplant, the market includes allograft, xenograft, autograft, allotransplantation, xenotransplantation, and others.

By end users, the market comprises transplant centers, hospitals, and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/organ-transplantation-market-915

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Acute Intermittent Porphyria Market Size And Key Trends In Terms Of Volume And Value 2020

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Acute Intermittent Porphyria Market Research Report - Forecast to 2023” Gives industry size, top players and worldwide demand

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Acute Intermittent Porphyria Market Research Report- Global Forecast till 2023” Gives industry size, top players and worldwide demand

Market Scenario

Acute intermittent porphyria (AIP) is a genetic metabolic disorder. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Generally, it is characterized by a deficiency of the enzyme porphobilinogen deaminase.

Also Read : https://www.medgadget.com/2018/08/silent-heart-attack-market-to-register-high-growth-during-forecast-period-2017-2023.html

The major causes of acute intermittent porphyria are abnormal urinary color, anorexia, insomnia, myalgia, and urinary retention. In some cases, AIP develops liver cancer (hepatocellular carcinoma), and some develop kidney failure. Other symptoms include gastrointestinal issues, urinary tract issues, neurological issues, psychiatric issues.

The acute intermittent porphyria market growth is majorly attributed to the increasing prevalence of the metabolic disorders, gastrointestinal issues, urinary tract issues, and healthcare insurance coverage. Moreover, increasing geriatric population will drive the market growth.

According to the Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia is likely to help the growth of the market over the forecast period.

According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

According to the American Liver Foundation, there is an increasing the prevalence of liver disease in the U.S. from then last few years. It further stated that at least 30 million people have some form of liver disease.

However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.

The global acute intermittent porphyria market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023.

Segmentations

The global acute intermittent porphyria market is segmented on the basis by diagnosis, by treatment, and by end user.

On the basis of diagnosis, it is segmented into blood test, urine test, serum test, DNA test, and others.

On the basis of treatment, it is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others.

On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.

Regional Analysis

The Americas dominate the global acute intermittent porphyria market owing to well-developed technology, increasing patient with genetic metabolic disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global acute intermittent porphyria market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing acute intermittent porphyria market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acute intermittent porphyria in the region.

On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Key Players

Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (U.S.).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Spinal Traction Market In Depth Study And Analysis Published, 2020

Market Research Future adds the “Spinal Traction Market Research Report - Forecast to 2022” report to their unique collection.

The World Spinal Traction Market report titled “Spinal Traction Market Research Report- Global Forecast to 2022” is an expert analysis report analyze by Key Players as DJO Global, STOLL Medizintechnik GmbH, RS Medical, Hill Laboratories Company, Mettler Electronics Corp, Antalgic-Trak, Medtronic and others. The Spinal Traction Market report summarizes on the basis of Types (manual spinal traction, mechanical spinal traction) by applications (slipped discs, bone spurs, degenerative disc disease, herniated discs, facet disease, sciatica, foramina stenosis, pinched nerves) by devices (continuous traction, gravity-dependent traction, manual traction) - Forecast to 2022.

Also Read : https://marketersmedia.com/spinal-traction-market-splendid-growth-by-key-players-share-revenue-and-demand-by-2022/246526

Spinal traction is a procedure of decompression therapy that releases pressure on the spine. It can be executed manually or mechanically. The Spinal Traction Market has been segmented on the basis of types which comprises of Manual spinal traction, Mechanical spinal traction. On the basis of applications the market is segmented into slipped discs, bone spurs, degenerative disc disease, herniated discs, facet disease, sciatica, foramina stenosis, pinched nerves and others. On the basis of devices the market is segmented into continuous traction, gravity-dependent traction, manual traction, others.

Spinal Traction Market Major TOC:

Research Methodology

Market Dynamics

Market Factor Analysis

Global Spinal Traction Market, by Types

Global Spinal Traction Market, by Material

Global Spinal Traction Market, by Applications

Global Spinal Traction Market, Company Landscape

Global Spinal Traction Market, by Region

Company Profile

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/spinal-traction-market-1902

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Integrated Cardiology Devices Market 2020 - Opportunity, Driving Trends And Deep Study 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Integrated Cardiology Devices Market Research Report – Forecast to 2023” Gives industry size, top players and worldwide demand

The Global Integrated Cardiology Devices Market Report is Recently Published By Market Research Future Firm. Report include market exclusive analysis on the basis of industry size, recent trends and demand supply. Market analysis is available on MarketResearchFuture.com uniquely by 80+ pages information, 30+ tables and 30+ figures exclusively.

Also Read : https://www.medgadget.com/2019/01/integrated-cardiology-devices-market-will-see-explosive-growth-at-12-4-cagr-by-2022-demand-analysis-by-jude-medical-edwards-lifesciences-corporation-abbott-laboratories-johnson-and-johnso.html

The Global Integrated Cardiology Devices Market is growing with a rapid pace. According to a recent study report published by the Market Research Future, the Global Integrated Cardiology Devices Market is booming and expected to gain prominence over the forecast period and is projected to grow a sound pace. The market is projected to demonstrate a sound growth by 2023, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017-2023).

Integrated cardiology devices are equipment which surgeons use for critical cardiac surgeries. These modern devices are extensively utilised for early diagnosis ensuring better treatment of various cardiovascular diseases. In recent years, growth has been observed in the integrated cardiology devices. Increase prevalence of the cardiovascular diseases is the major driving factor for the market growth. According to World Health Organization, approximately 30% of the deaths across the globe are caused due to heart diseases. Moreover, growing adoption rates of minimally invasive surgeries favoured by continuous developments within the healthcare sector boost the market growth. However, factors such as lack of awareness and expensive treatment is estimated to restrain the market growth during the forecast period.

The Global Integrated Cardiology Devices Market is expected to grow at a CAGR of 12.4% during forecasted period 2017-2023.

Segmentation

The Global Integrated Cardiology Devices Market is segmented on the basis of types, applications and end users.

Based on types, the market is segmented as Cardiology EMR Software, EHR (Electronic health record), FFR (fractional flow reserve), Optical Coherence Tomography, others.

On the basis of application, they are segmented sudden cardiac arrest, internal monitoring, Cardiac resynchronization therapy, Cardiothoracic surgery, others. Cardiac Resynchronization Therapy (CRT) is an effective therapy in heart failure.

On the basis of end users, the market is segmented into catheterization laboratories, Hospitals and others.

Key Players:

Market Research Future (MRFR) recognizes the following companies as the key players in Integrated Cardiology Devices Market: There are plenty of large and small market players which operate in this market all over the globe.

Medtronic (US),
Boston Scientific Corporation (US),
Jude Medical (US),
Edwards Lifesciences Corporation (US),
Abbott Laboratories (US),
Johnson and Johnson (US),
Getinge (Sweden),
Terumo Corporation (Japan),
Lepumedical (Bejing),
Acrostak (Switzerland),
Koninklijke Philips N.V. (Netherlands),.
Athenahealth, Inc. (U.S)

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in Integrated Cardiology Devices Market and to maintain their market position.

In August, 2017- Medtronic, the global leader in medical technology, completed their acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure. HeartWare became part of the Heart Failure business within the Medtronic Cardiac Rhythm and Heart Failure division. Under the terms of the transaction, each outstanding share of HeartWare common stock was converted into the right to receive USD 58.00 in cash.

In January, 2017- Abbott completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The transaction provided Abbott with expanded opportunities for future growth and is an important part of the company’s ongoing effort to develop a strong, diverse portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals.

In July, 2016- Boston Scientific Corporation acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The Cosman Medical team and products became a part of the Boston Scientific Neuromodulation business, which offered a range of Spinal Cord Stimulator (SCS) systems to treat patients with chronic pain, and Deep Brain Stimulation systems for the treatment of Parkinson’s disease, dystonia and essential tremor.

In September, 2016- Johnson & Johnson announced that the company entered into a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for USD 4.325 billion in cash. AMO reported sales of USD 1.1 billion for 2015. The acquisition included ophthalmic products in three business segments: cataract surgery, laser refractive surgery and consumer eye health.

Regional Analysis:

The Americas accounts for a significant market share. High healthcare expenditure, rising number of the cardiac services, especially within the U.S. and Canada region are the major drivers for market growth within the region. Europe is the second largest market in the world. Growing medical devices industry and healthcare penetration drives the market within the region. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large medical devices industry. Asia Pacific region is expected to grow rapidly. On the other hand, the Middle East and Africa region holds the least market share.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/integrated-cardiology-devices-market-1189

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Companion Animal Healthcare Market Size And Key Trends In Terms Of Volume And Value 2020

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Companion Animal Healthcare Market Research Report – Forecast to 2023” Gives industry size, top players and worldwide demand

The Global Companion Animal Healthcare Market is predicted to touch USD 20 billion at a 9.6% CAGR over the forecast period (2017-2023), as per the latest Market Research Future (MRFR) report.

Segmentation – Companion Animal Healthcare Market

The Market Research Future report provides a wide segmental analysis of the companion animal healthcare market based on end users, diagnostic tests, and product.

Also Read :https://www.medgadget.com/2019/11/companion-animal-healthcare-market-2019-share-size-trends-growth-regional-analysis-with-global-industry-forecast-to-2023.html

Based on product, the companion animal healthcare market is segmented into vaccines, pharmaceuticals, and feed additives. The feed additives segment is again segmented into medicinal feed additives and nutritional feed additives. The nutritional feed additives segment is further segmented into vitamins, minerals, and proteins, and medicinal feed additives are further segmented into probiotics and prebiotics, immune-modulators, enzymes, hormones, and others. The pharmaceutical products segment is further segmented into anti-inflammatories, antibiotics, and anti-infectives. Of these, the pharmaceutical products segment will have the largest share in the market over the forecast period. This is owing to the rising prevalence of food-borne diseases, brucellosis as well as other zoonotic diseases which are hazardous to animals.

Based on diagnostic tests, the companion animal healthcare market is segmented into molecular diagnostics, immunodiagnostic tests, diagnostic imaging, and others. Of these, the diagnostics imaging segment will dominate the market over the forecast period. This is owing to rising zoonotic infections that is boosting the need for establishing point-of-care testing and diagnostics laboratories.

Based on end users, the companion animal healthcare market is segmented into home care, veterinary clinics, and veterinary hospitals. Of these, the veterinary clinics and veterinary hospitals will lead the market over the forecast period. This is owing to the accessibility of a huge variety of diagnostic options.

Market Overview nd Drivers

Companion animals are used for amusement, company, extrovert display, psychological support, and other functions which humans require for sharing with animals. A yearly veterinary checkup is one of the finest means of keeping the pet healthy.

Various factors are propelling the companion animal healthcare market growth. These factors, as stated by the MRFR report, include growing pet adoption across the world, increasing government initiatives for animal health, growing advancements in technology in animal healthcare, and increasing nuclear families that have accelerated the trend of pet ownership. Additional factors pushing market growth include growing investments made by key players for developing advanced pet care solutions, increasing awareness about animal cruelty, advances in animal vaccines and health medicines, and increased types of medical treatment.

Key Players – Companion Animal Healthcare Market

Leading players profiled in the companion animal healthcare market report include

Boehringer Ingelheim (Germany),
Perrigo Company plc (Ireland),
Vetoquinol S.A. (France),
Bayer Animal Health (Germany),
Elanco Animal Health (US),
Merial (France),
Virbac Animal Healthcare (France),
Ceva Animal Healthcare (UK),
Merck and Co., Inc. (US),
Zoetis Animal Healthcare (US),

among others. Key players have acquired several strategies to gain a competitive edge in the market. This include product launch, expansion, partnership, collaboration, and acquisition.

Competitive Analysis – Companion Animal Healthcare Market

Characterized by the presence of several well-established and small players, the global Market of Companion Animal Healthcare appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing. The Market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.

However, well established players integrate acquisition, collaboration, partnership, expansion, and product launch to gain competitive advantage in this market.

For instance; innovative Seresto collar by Bayer to protect dogs and cats against diseases transmitted by parasites. These key players offer a broad range of products with a range of treatment options, especially for bacterial infections.

Zoetis Animal Healthcare is one of the global animal healthcare company provides wide range of products for animal care. Moreover, company provides specific products for dogs, cats and horses. For instance, Apoquel, Cerenia, Convenia, Cytopoint, Palladia, Rimadyl are the products for dogs.

Regional Analysis – Companion Animal Healthcare Market

Based on the region, the companion animal healthcare market report covers the latest trends and growth opportunities across the Asia Pacific, Europe, the Americas, and the Middle East and Africa. Of these, the Americas will spearhead the market over the forecast period. This is owing to the availability of a huge variety of animal health products.

The companion animal healthcare market in Europe is predicted to have the second-largest share in the market over the forecast period. This is due to an increase in pet ownership on account of tax benefits offered by the government.

The companion animal healthcare market in the APAC region is predicted to have a positive and steady growth over the forecast period. This is owing to the rising awareness about animal cruelty that has influenced people awareness as well as ideologies towards animals.

The companion animal healthcare market in the Middle East and Africa is predicted to have a steady growth over the forecast period. This is owing to high growth opportunities on account of financial improvement and an associated increase in disposable income.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/companion-animal-Healthcare-market-1168
About Market Research Future:

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Fertility Services Market 2020 - Opportunity, Driving Trends And Deep Study 2025

Market Highlights

Global Fertility Services Market size is expected to register a CAGR of 8.99% during the forecast period, with a market value of USD 44,136.91 Million by 2025. Fertility services are procedures or treatments used to cure genetic and fertility issues and assist with conception. These services include assisted reproductive technology (ART) methods and drugs that help infertile couples in planning a family.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6281

Segment Analysis

The Global Fertility Services Market has been segmented by underlying cause and treatment.

Based on the underlying cause, the fertility services market has been segregated into female infertility and male infertility.

The Global Fertility Services Market, based on the treatment, has been segmented into ART and infertility drugs. The ART treatment has been further segmented into in-vitro fertilization (IVF), frozen embryo replacement (FER), artificial insemination, and others.

Regional Analysis

The Global Fertility Services Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Europe is expected to dominate the global fertility services market. This can be attributed to the lower fertility rate in the region and increasing IVF tourism in Spain. For instance, according to the European Society of Human Reproduction and Embryology (ESHRE), Spain is the preferred destination by foreigners for reproductive procedures, representing almost 40% of European fertility tourism, which is estimated to rise in the future. Moreover, easy reimbursement policies and increasing obesity cases are also expected to drive market growth.

The Americas market for fertility services is estimated to be the second-largest during the review period. The high number of ART procedures in the US is expected to boost the growth of the regional market. For instance, as per the data mentioned by the Centers for Disease Control and Prevention, in 2017, nearly 284,385 ART cycles were performed at 448 clinics in the US. Additionally, late pregnancies and the high adoption rate of IVF treatment are further fueling the market growth.

Asia-Pacific is estimated to be the fastest-growing market owing to the declining fertility rates in the region. According to the data suggested by the World Bank, the fertility rate in Japan decreased at a rate of 1.6 in 2016. Moreover, fertility disorders followed by favorable reimbursement scenario is also positively affecting the market growth.

The market in the Middle East & Africa is expected to witness steady growth due to the reduced ovarian reserve in women in the Middle Eastern countries.

Key Findings of the Study

The Global Fertility Services Market is estimated to reach USD 44,136.91 Million by 2025 at a CAGR of 8.99% during the assessment period

Europe accounted for the largest share of the global fertility services market due to the low fertility rate and increasing obesity rate

Based on the underlying cause, the female infertility segment accounted for the largest market share of 5% in 2018

Based on treatment type, the Assisted Reproductive Technology (ART) segment accounted for the largest market share of 21% in 2018

Key Players

MRFR recognizes the following companies as the Key Players in the Global Fertility Services Market— Merck KGaA (Germany), CooperSurgical, Inc. (US), Care Fertility (UK), Ferring B.V. (Switzerland), INVO Bioscience (US), Vitrolife (Sweden), Monash IVF Group (Australia), Cook (US), FUJIFILM Irvine Scientific (US), and Kitazato Corporation (Japan).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/fertility-services-market-6281

Dietary supplements Market 2020 - Opportunity, Driving Trends And Deep Study 2023

Market Scenario:

Historically, dietary supplements marketing has focused on promoting a specific specialty ingredient targeted at specific consumer health needs such as omega 3 for heart health, lutein for eye care and others. Personalized nutrition offers manufacturers, the chance to develop a relationship with consumers rather than a single transactional approach. Massive advancements in the dietary supplements preparation in the field of personalized nutrition along with the possibility of the superior drug formulation will uplift the U. S. dietary supplements in the age of personalized nutrition market. The economies of scale and scope resulting out of greater demand for dietary supplements is expected to significantly reduce the final price of the products thus benefiting the final consumers. Thus, increasing the prevalence of cancer and metabolic diseases will result in arise in the volume of the dietary supplements market.

Dietary supplements in an age of personalized nutrition is regarded as one of the most noteworthy changes in the healthcare sector because of its capability to provide improved drug delivery and better patient/individual treatment process. Massive advancements in the dietary supplements preparation in the field of personalized nutrition along with the possibility of the superior drug formulation will uplift the U. S. dietary supplements in the age of personalized nutrition market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5644

However, spurious and misbranded products and safety concerns of dietary supplements affect the growth of the U. S. dietary supplements in the age of personalized nutrition market negatively.

The U. S. dietary supplements in the age of personalized nutrition market is expected to grow at a CAGR of 7.95% during the forecast period 2017-2023.

Intended Audience:

Dietary Supplements Manufacturers
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors

Segmentation

The U. S. dietary supplements in the age of personalized nutrition market is segmented by product category, application, gender, dosage form and end-user.

By the product category, it is segmented into vitamins, herbs & botanicals, sports supplements, meal supplements, minerals and other.

By the application, it is segmented into lifestyle diseases, inherited diseases, genetic predispositions and others.

By the gender, it is segmented into female and male. Female and male is further segmented into various age groups, namely, 55 + age group, 35-54 age group, 19-34 age group, and 0-18 age group.

By the dosage form, it is segmented into tablets, capsules, powder, liquids, soft gels and others.

By the end-users, it is segmented into hospitals & clinics, home care, and others.

Key Findings

The U. S. dietary supplements in the age of personalized nutrition market was USD 18,093.1 million in 2016
Vitamins is the largest segment, by product category which is projected to grow at a CAGR of 8.37% during the forecast period from 2017-2023
Female is the largest segment, by gender in S. and expected to grow at a rate of CAGR 8.45% during the forecast period
The tablets segment accounted for the largest market share with 28.3% for the U.S. dietary supplements in the age of personalized nutrition market by dosage and is expected grow with the CAGR of 8.44% for the forecast period.

Key Players

Some of the key players in this market are Nestlé Health Science, Danone Nutricia, Carlyle Group, Amway (Nutrilite), Archer Daniels Midland, Abbott Laboratories, Herbalife International, Amway, Danisco, Glanbia, Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Balchem Corporation, Natures Product Inc., Bactolac Pharmaceutical Inc. and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/u-s-dietary-supplements-market-5644